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Signal Thresholds and Modular Synergy During Expression of
Costimulatory Molecules in B Lymphocytes
Krishnamurthy Natarajan, Naresh C. Sahoo, and Kanury V. S. Rao1
We analyzed intracellular pathways modulating surface densities of CD80 and CD86 in B cells activated through ligation of the
Ag receptor, and the adhesion molecule CD54. Whereas B cell Ag receptor (BCR) cross-linking alone stimulated increased
expression of CD86, up-regulation of CD80 required dual stimulation with anti-IgM and anti-CD54. The principal downstream
component contributed by BCR signaling, toward both CD80 and CD86 induction, was the elevated concentration of free cyto-
plasmic Ca21, recruited by way of capacitative influx. This alone was sufficient to generate an increase in CD86 levels. However,
CD80 enhancement required the concerted action of both intracellular Ca21 concentration and CD54-initiated pathways. The
nexus between anti-IgM and anti-CD54 stimulation, in the context of CD80 regulation, was identified to involve a self-propagating
process of sequential synergy. The first step involved amplified accumulation of intracellular cAMP, as a result of cross-talk
between BCR-mobilized Ca21 and CD54-derived signals. This then facilitated a second synergistic interaction between Ca21 and
cAMP, culminating in CD80 expression. Our findings of distinct signal transducer requirements, with the added consequences of
cross-talk, offers an explanation for variable modulation of costimulatory molecule expression in response to diverse physiological
stimuli. Importantly, these results also reveal how concentration threshold barriers for recruitment of individual second messen-
gers can be overcome by constructive convergence of signaling modules. The Journal of Immunology, 2001, 167: 114–122.
E xtensive studies from a variety of laboratories have de-tailed both the initiation and propagation of protein phos-phorylation cascades that emanate upon ligation of the B
cell Ag receptor (BCR)2 (1–6). This process is initiated by the
tyrosine phosphorylation of immunoreceptor tyrosine-based acti-
vation motif (ITAM) sequences within Iga and Igb by the src
family of protein tyrosine kinases. As a consequence of this, at
least three major pathways are recruited. These include pathways
that are dependent upon phospholipase Cg, the Rho family of GT-
Pases, or the Ras/phosphatidylinositol-3-kinase (4–6). Although
much of the current emphasis of research on signal transduction in
lymphocytes has focused on the initial events that follow receptor
triggering, the various downstream mechanisms that eventually
culminate into modification of lymphocyte function remain
unknown.
One important consequence of BCR ligation is the regulated
expression of a variety of cell surface molecules such as the MHC
class II, costimulatory, and adhesion molecules (7–11). It is the
cumulative phenotypic composition of the surface that then defines
functional properties of the B cell, either in terms of its Ag pre-
senting or migratory capabilities (10, 12, 13). Although BCR
cross-linking constitutes the principal trigger that initiates activa-
tion of B cells and their induction into a response, it is now be-
coming clear that this effect can be modulated by signals generated
from other molecules on the cell surface (14). For example,
whereas coligation of BCR with the CR2/CD19/TAP-1 complex
leads to increased B cell proliferation (15, 16), cross-linking of
BCR with the FcgRIIb coreceptor has been found to be inhibitory
(17–20). Similarly, reciprocal desensitization of MHC class II and
BCR signaling has also been recently demonstrated (21).
Thus, while the regulatory influences of cell surface accessory
molecules on BCR signaling is being increasingly recognized, the
mechanisms through which independently generated biochemical
pathways interface and, thereby, modulate cell function remains
poorly understood. To gain further insights into this aspect, we
examined the induction of CD80 (B7-1) and CD86 (B7-2) in
splenic B cells under a defined set of conditions. As shown earlier
by us (22) and others (10), moderate cross-linking of the BCR was
sufficient to enhance surface levels of CD86 but not CD80. The
latter required provision of an additional stimulus either in the
form of a cytokine or ligation of a second molecule on the B cell
surface (22–24). In this study, the additional stimulus used was
anti-CD54 (ICAM-1) which, in conjunction with anti-IgM treat-
ment, led to a marked enhancement in CD80 levels. Using such a
system, we demonstrate how distinctions in both the concentration
and spectrum of key second messenger intermediates can account
for the distinct induction thresholds of these two molecules. Fur-
thermore, our data also reveal the existence of a novel process of
sequential synergy that is involved during CD80 up-regulation.
Finally, present findings also provide a preliminary insight into
how B cell responsiveness—at least in the context of costimulatory
molecule expression—can be variably modulated by diverse phys-
iological stimuli.
Materials and Methods
Materials
mAbs against mouse molecules CD80 (clone 1G10), CD86 (clone GL-1),
CD54 (clone 3E2), B220 (clone RA3-6B2), and isotype-matched controls
were obtained from BD PharMingen (San Diego, CA). Goat anti-mouse
IgM was purchased from Sigma (St. Louis, MO). Ab-coated magnetic
Immunology Group, International Centre for Genetic Engineering and Biotechnology,
Aruna Asaf Ali Marg, New Delhi, India
Received for publication February 8, 2001. Accepted for publication April 23, 2001.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked advertisement in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Address correspondence and reprint requests to Dr. Kanury V. S. Rao, Immunology
Group, International Center for Genetic Engineering and Biotechnology, Aruna Asaf
Ali Marg, New Delhi 110 067, India. E-mail address: kanury@icgeb.res.in
2 Abbreviations used in this paper: BCR, B cell Ag receptor; PKC, protein kinase C;
PKA, protein kinase A; db-cAMP, dibutyryl cAMP; TMB-8, 8-(diethylamino)octyl-
3,4,5-trimethoxybenzoate; H89, N-[2-((p-bromocinamyl)amino)ethyl]-5-isoquino-
linesulfonamide; KN-62, 1-[N,O-bis-(5-isoquinolinesulfonyl)N-methyl-L-tyrosyl]-4-
phenylpiperazine; fluo-3-AM, fluo-3-acetoxymethyl ester; Cai21, intracellular
calcium ion.
Copyright © 2001 by The American Association of Immunologists 0022-1767/01/$02.00
 o
n
 M
ay 26, 2011
w
w
w
.jimmunol.org
D
ow
nloaded from
 
beads for the purification of B lymphocytes were obtained from Miltenyi
Biotec (Auburn, CA). Inhibitors to various kinases such as genistein, calphos-
tin C, 1-[N,O-bis-(5-isoquinolinesulfonyl)N-methyl-L-tyrosyl]-4-phe-
nylpiperazine (KN-62), calmidazolium, cyclosporin A, EGTA, and other
reagents such as guanidine isothiocyanate and dibutyryl-cAMP (db-cAMP)
were obtained from Sigma (St. Louis, MO). Ionomycin, 8-(diethylamino)oc-
tyl-3,4,5-trimethoxybenzoate (TMB-8), N-[2-(( p-bromocinamyl)amin-
o)ethyl]-5-isoquinolinesulfonamide (H89), fluo-3-acetoxymethyl ester (fluo-
3-AM), Abs to Ser133-phosphorylated CREB, and CREB were purchased
from Calbiochem (San Diego, CA). Intracellular cAMP levels were mea-
sured using the BIOTRAK EIA cAMP detection kit from Amersham (Ar-
lington Heights, IL). Primers specific for the b-actin gene were obtained
from Promega (Madison, WI).
In these studies, the anti-IgM and anti-CD54 Abs were used as their F(ab)2
fragments, which were obtained by digestion with pepsin, followed by puri-
fication over a protein G-Sepharose column as described earlier (25).
Animals
Female BALB/c mice (6–8 wk old), maintained under pathogen-free con-
ditions, were obtained from the small experimental facility of our institute.
Enrichment of B lymphocytes
This was achieved by negative selection, through magnetic sorting, essen-
tially as described previously (22). Briefly, splenocytes from 6- to 8-wk-old
BALB/c mice were first depleted of adherent cells by panning over plastic
plates. From this, T cells were removed by two rounds of incubation with
a mixture of magnetic beads individually coated with anti-CD4, anti-CD8,
and anti-CD90 (Thy 1.2) (Miltenyi Biotec). Furthermore, the IgG1 popu-
lation was also removed by additional incubation of cells with anti-mouse
IgG-coated microbeads. Separation was achieved using MACS columns
(Miltenyi Biotec). The purity of the resulting population of B cells obtained
in this fashion was 95–98% when measured as B220-PE-stained cells by
flow cytometry.
Stimulation of B cells and analyses of CD80 and CD86
expression by flow cytometry
Enriched B cells were plated in 96-well plates at 3 3 105/well in 0.1 ml of
RPMI 1640 containing 10% FCS and antibiotics (RPMI 10). Depending on
the requirement, cells were cultured with the F(ab)2 fragment of anti-IgM
(10 mg/ml), and/or anti-CD54 (10 mg/ml), and/or ionomycin (0.5 mM). In
initial experiments, stimulation times were varied from 2 to 24 h for CD86
analysis, and from 2 to 60 h when CD80 levels were being monitored.
Although a 2-h stimulation time with anti-IgM was sufficient to induce
CD86, significant CD80 up-regulation required between 8 and 12 h of
treatment with the combination of anti-IgM plus anti-CD54. Consequently,
a standard stimulation time of 12 h was used for all of the experiments
reported here. For the effects of inhibitors, cells were pre-equilibrated with
EGTA (3 mM), genistein (60 mg/ml), calphostin C (0.1 mM), calmidazo-
lium (20 nM), KN-62 (5 mM), cyclosporin A (8 mM), or H89 (100 nM) for
1 h before addition of the appropriate stimuli. At the end of incubation, the
cells were washed thoroughly in ice-cold HBSS to remove all traces of
excess stimuli and inhibitors, and cultured again in complete medium
(RPMI 1640 containing 10% FCS) for the requisite time. Based on the
kinetics of induction of CD80 and CD86 (see Fig. 1A, c), CD86 levels were
measured at 24 h poststimulation with anti-IgM or ionomycin, whereas
CD80 was measured at 60 h after addition of the appropriate stimulants.
The viability of cells was at least 95%, as determined by trypan blue ex-
clusion, for all the analyses reported here.
At the end of the requisite culture period, the Fc receptors on the cells
were blocked with anti-CD16/CD32 (BD PharMingen) before analysis.
Following this, cells were stained with biotinylated anti-B220 (1 mg/106
cells for 1 h at 4°C) and then labeled with streptavidin-PE. After adequate
washes (PBS with 0.5% BSA and 0.01% azide), cells were subjected to a
second round of staining with FITC-conjugated Abs against either CD80 or
CD86 (1 mg/106 cells for 1 h at 4°C) and then fixed in buffer containing
0.1% paraformaldehyde.
Two-color analysis was conducted on a FACSCalibur flow cytometer
(BD Immunocytometry Systems, Mountain View, CA). Logarithmically
amplified fluorescence data were collected on 5 3 104 viable cells as de-
termined by forward scatter intensity and by exclusion of propidium io-
dide-stained cells.
Quantitation of CD80 and CD86 mRNA levels
Total cellular RNA was extracted from cultured cells at the time point
indicated in figure legends using guanidine isothiocyanate followed by acid
phenol treatment. Total RNA (10 mg) was fractionated on a formaldehyde
agarose gel, transferred onto Hybond-N nylon membrane (Amersham), and
subsequently probed with 32P-labeled gene-specific full-length probes for
CD80 and CD86. The blots were exposed to x-ray films and developed
later. Following this, blots were stripped off the initial probe and then
hybridized with 32P-labeled probes for b-actin as loading controls.
Monitoring intracellular Ca21 levels
Enriched B cells (2 3 107) were incubated with 1 mM fluo-3-AM in 1 ml
of culture medium for 45 min at 37°C. Thereafter, the cells were washed
thoroughly in HBSS and finally resuspended at 1 3 106 cells/ml of culture
medium alone or in medium containing either 3 mM EGTA or 50 mM
TMB-8. After a 15-min incubation at room temperature, cells were stim-
ulated with the appropriate agents and the resultant variation in intracel-
lular Ca21 was monitored by flow cytometry.
Estimation of intracellular levels of cAMP
Enriched B cells that had been cultured for 12 h were transferred into
serum-free medium and equilibrated over an additional 4 h of culture.
Following this the cells were washed and resuspended in serum-free me-
dium at 1 3 106 cells/ml, and 100-ml aliquots were plated into wells of a
96-well tissue culture plate. Quadruplicate sets of wells were stimulated
with the appropriate agent (or mock-stimulated with carrier only) for 1 h at
37°C. The resulting intracellular cAMP levels were then measured in cell
lysates using the BIOTRAK EIA kit (Amersham) strictly following the
protocol recommended by the manufacturer.
To determine the effects of exogenous addition of db-cAMP on intra-
cellular cAMP levels, cells prepared as above were incubated with varying
concentrations of db-cAMP for 1 h at 37°C. Following this, the cells were
washed extensively in serum-free medium to remove any traces of excess
db-cAMP. The remaining procedure was identical with that described
above.
Analysis of CREB phosphorylation
Enriched B cells were equilibrated either in the presence or absence of
various inhibitors for 1 h before stimulation with the appropriate agents for
30 min at 37°C. At the end of this the cells were chilled on ice, washed with
ice-cold PBS, and lysed in lysis buffer (10 mM HEPES (pH 7.9); 10 mM
KCl; 0.1 mM EDTA; 0.1 mM EGTA, 0.5% Nonidet P-40, and 2 mg/ml
each of aprotinin, leupeptin, and pepstatin). The resulting nuclear pellet
was then extracted in buffer containing 20 mM HEPES (pH 7.9); 0.4 M
NaCl; 1 mM EDTA; 1 mM EGTA; and 2 mg/ml each of aprotinin, leu-
peptin, and pepstatin.
Nuclear extracts from 1 3 107 cells were each resolved on 10% SDS-
polyacrylamide gels and subsequently transferred onto a nitrocellulose
membrane (Hybond C1; Amersham). The resulting blots were probed with
rabbit Abs specific for Ser133-phosphorylated CREB, followed by HRP-
labeled secondary Abs. Blots were developed by chemiluminescence using
the ECL kit (Amersham). To verify comparable loading of proteins, bound
Abs were stripped off, and the blots were subjected to a second round of
screening with anti-CREB Abs.
Results
BCR-dependent induction of CD86 and CD80 levels in B cells
Stimulation of splenic B cells with anti-IgM Abs (see Material and
Methods) induced increased surface expression of CD86 (Fig. 1A),
although no concurrent effect on CD80 was noted (data not
shown). However, enhanced surface expression of CD80 could
readily be obtained upon dual stimulation of cells with a combi-
nation of anti-IgM and anti-CD54 (ICAM-1) Abs (Fig. 1A, b).
Both of these stimuli were found to be obligatory, because addition
of either component alone had no detectable effect on CD80 levels.
This contrasted with the effect on CD86, where stimulation with
the combination of anti-IgM and anti-CD54 did not yield any sig-
nificant enhancement in levels over that obtained with anti-IgM
stimulation alone (data not shown). In addition to distinct stimulus
requirements, the kinetics of induction of these two molecules also
differed as shown in Fig. 1A, c. When compared with CD86, CD80
showed delayed induction becoming apparent only several hours
after initiation of stimulation (Fig. 1A, c). This observed enhance-
ment in surface densities of CD80 and CD86 in response to the ap-
propriate stimuli also correlated well with a concomitant
increase in the respective mRNA levels as shown in Fig. 1B. The
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magnitude of increase in cellular mRNA content observed in Fig.
1B may likely reflect increased transcriptional activation of genes
for both CD80 and CD86. However, the alternate possibility that
this increase derives from enhanced message stability cannot pres-
ently be ruled out.
Induction of both CD80 and CD86 in response to the appropri-
ate stimuli could be inhibited by the inclusion of genistein, a broad
spectrum inhibitor of protein tyrosine kinases (26). This inhibition
was exercised at the level of cell surface protein (Fig. 1A), as well
as at that of the respective mRNAs (Fig. 1B). These latter results
imply the dependence of both CD80 and CD86 regulatory path-
ways on the tyrosine phosphorylation events initiated upon recep-
tor ligation.
Intracellular calcium ion (Cai21) concentrations modulate
expression of both CD80 and CD86
To dissect biochemical mediators of the above response, we next
examined the effects of addition of a variety of pharmacological
inhibitors. In the course of these studies, we observed that addition
of either TMB-8 or EGTA completely abolished both anti-IgM-
dependent CD86 up-regulation and CD80 up-regulation mediated
by anti-IgM plus anti-CD54. Whereas TMB-8 is known to inhibit
Ca21 release from intracellular stores (27), EGTA blocks its influx
from the extracellular milieu (28). Importantly, the inhibitory ef-
fects of these two agents were enforced not only at the level of cell
surface protein, but also at that of the corresponding transcripts.
The results with EGTA as a representative are shown in Fig. 2.
The inhibitory effects of TMB-8 and EGTA together implicated
a role for Cai21 in the mediation of expression of both CD80 and
CD86. Consequently, we next examined the effects of BCR and
CD54 ligation on Cai21 mobilization. Consistent with prior find-
ings (for a review, see Ref. 29), stimulation of B cells with anti-
IgM resulted in a biphasic recruitment of Ca21 ions into the cy-
toplasm. A rapid, but transient, increase was evident immediately
upon addition of anti-IgM (Fig. 3A). Although these levels de-
clined rapidly, they nevertheless stabilized at concentrations sig-
nificantly above the baseline (Fig. 3A). Although the first, rapid,
phase has been attributed to 1,4,5-inositol triphosphate-mediated
release from intracellular stores, the second phase of low but sus-
tained elevation has been ascribed to represent capacitative influx
mediated by the calcium-release activated channels (CRAC) (29–
31). These latter channels are activated upon exhaustion of the
internal pool, although the mechanism by which this occurs is not
known (31).
In keeping with the above interpretation, addition of TMB-8
markedly inhibited Cai21 mobilization by B cells, in response to
anti-IgM stimulation (Fig. 3A). As opposed to this, EGTA addition
selectively suppressed anti-IgM-mediated capacitative Ca21 in-
flux, with only a relatively minor effect on recruitment from in-
tracellular stores (Fig. 3A).
Distinct from the effects of anti-IgM, stimulation of B cells with
anti-CD54 had no detectable influence on Cai21 concentrations
(Fig. 3A). Furthermore, dual stimulation with both anti-IgM and
anti-CD54 also produced no additive effect, yielding a profile iden-
tical with that obtained upon stimulation with anti-IgM alone (data
not shown). Our findings of the absence of any effect of anti-CD54
on Cai21 concentrations in B cells is in keeping with prior find-
ings. In a recent study, van Horssen et al. (32) also did not detect
Cai21 mobilization in B cells upon CD54 ligation although CD54
cross-linking has been shown to enhance Cai21 concentrations in
rat endothelial cells (33). Thus, whereas Cai21 was identified as a
common mediator of both the CD80 and CD86 regulatory path-
ways, its intracellular mobilization appeared to exclusively derive
FIGURE 1. Induction of CD80 and CD86 in murine B cells. A, Cell
surface staining for CD86 (a) or CD80 (b) in B2201 gated cells that were
either left unstimulated (thin line) or stimulated (thick line) with either
anti-IgM (a) or anti-IgM plus anti-CD54 (b). A parallel set of cells were
also stimulated in the presence of genistein. Although the results for CD80
are shown by the dashed line (b), the corresponding profile for CD86 was
superimposable over that obtained for unstimulated cells. c, Kinetics of
induction of CD86 (E) and CD80 (F) in appropriately stimulated cells. A
Northern blot analyses, using cDNA probes, for the corresponding mRNA
species is also shown in B. For CD86, mRNA extracts were prepared at
24 h after initiation of stimulation, whereas extracts for CD80 mRNA
analysis were prepared 48 h later. Data in A are representative of at least
five separate experiments, whereas those in B are from one of three
experiments.
FIGURE 2. EGTA inhibits induction of both CD80 and CD86. The ef-
fects of EGTA addition (dashed line) on either anti-IgM-dependent CD86
induction (a) or anti-IgM plus anti-CD54-mediated CD80 up-regulation (b)
are shown in A. In both cases, unstimulated cells are represented by the thin
line, and staining in cells stimulated in the absence of EGTA are depicted
by the thick line. The corresponding effects of EGTA on the respective
mRNA levels are also shown in B. Data presented here are a representative
of four separate experiments.
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due to BCR and not CD54 triggering. Furthermore, the inhibitory
effect of EGTA on both CD80 and CD86 induction also localizes
the capacitative influx phase of BCR-dependent Cai21 recruitment
as the key regulatory component.
The above identification of a role for BCR-mediated capacita-
tive Ca21 influx also prompted us to next single out the effects due
to this second messenger. Influx of Ca21 from the extracellular
milieu can readily be achieved by the use of ionophores such as
ionomycin (34, 35). However, to maintain parity with the native
situation, we first performed titration experiments to determine that
dose of ionomycin that would induce Ca21 influx to a level that
was comparable with that obtained upon anti-IgM (or anti-IgM
plus anti-CD54) stimulation. For this, B cells were treated with
varying concentrations of ionomycin, and the resultant Ca21 influx
was monitored. The cumulative results from such experiments are
shown in Fig. 3B. It is evident from this figure that treatment of
cells with an ionomycin concentration of 0.5 mM mimics the ca-
pacitative entry phase of anti-IgM-stimulated recruitment of
calcium ions.
To ascertain the specific effects of this Cai21 concentration, we
next used 0.5 mM ionomycin as the stimulant. As shown in Fig.
3C, this treatment alone was sufficient to generate an increase in
surface CD86 expression. Importantly, the magnitude of this effect
was comparable to that obtained upon anti-IgM stimulation and,
furthermore, was EGTA sensitive (Fig. 3C). In contrast to its effect
on CD86, treatment of cells with 0.5 mM ionomycin alone had no
detectable effect on surface CD80 levels (Fig. 3D). However,
CD80 up-regulation was readily achieved with a combination of
0.5 mM ionomycin and anti-CD54 (Fig. 3D). The extent of en-
hancement was comparable to that observed with the combination
of anti-IgM plus anti-CD54 (Fig. 3D). As expected, this effect was
also inhibited upon addition of EGTA (Fig. 3D).
The collective observations in Fig. 3, C and D, that 0.5 mM
ionomycin could duplicate the effects of anti-IgM on both CD80
and CD86 up-regulation, further underscores the relevance of
Cai21 in both pathways. Importantly, these findings support that
BCR-mediated capacitative Ca21 influx is at least sufficient to ac-
count for the effect of anti-IgM on induction of both CD80 and
CD86. In the context of the present system, the results in Fig. 3
also reveal a dual role for Cai21. Whereas on the one hand it
ensures CD86 induction, it also appears to act in concert with
CD54-dependent pathways to facilitate CD80 up-regulation.
cAMP is the second intracellular messenger that governs CD80
expression
Our identification of the regulatory intermediate provided upon
BCR stimulation encouraged us to explore for a possible counter-
part that could be implicated in the CD54-dependent pathways. In
this connection, earlier studies have shown that addition of db-
cAMP could result in CD80 up-regulation in B lymphoma cells
(36). However, the db-cAMP concentration required was high
(600 mM), and the extent of enhancement (;2-fold) was modest
(36). In addition to this, it has also been demonstrated in rat as-
trocytes that engagement of CD54 by specific Ab induced intra-
cellular cAMP accumulation (37). Taken together, these studies
raised the possibility that cAMP could well constitute a mediator
of CD54-dependent effects on CD80 levels.
We first examined the effects of either anti-IgM, ionomycin (0.5
mM), anti-CD54, or relevant combinations of these, on cAMP lev-
els within B cells. The results from such experiments are summa-
rized in Fig. 4A. As expected on the basis of earlier reports (38),
FIGURE 4. Regulation of intracellular cAMP and its consequences on
costimulatory molecule expression. The data in A depict the effect of the
various stimuli used on intracellular cAMP concentrations in purified B
cells. In a separate experiment, cells were also stimulated with indicated
concentrations of db-cAMP, and the resultant intracellular accumulation
was measured (B). The lines intercepting the graph, numbered 1 and 2,
represent intracellular cAMP concentrations (dashed lines representing
SD) obtained in response to stimulation of cells either with anti-IgM plus
anti-CD54, or with anti-CD54 alone, respectively. The data in C depict cell
surface CD80 staining in B2201 gated cells in response to the indicated
stimuli. Cells, Unstimulated; aIg, anti-IgM; In, 0.5 mM ionomycin; dbc
(20), 20 mM db-cAMP; dbc (100), 100 mM db-cAMP; aCD, anti-CD54.
Values are the mean (6SD) of at least four separate experiments.
FIGURE 3. Cai21 mobilization and its effect on CD80 and CD86 levels.
fluo-3-AM-loaded B cells were stimulated with anti-IgM either in the ab-
sence (profile 1) or presence of either EGTA (profile 2) or TMB-8 (profile
3), and the subsequent recruitment of Cai21 was monitored by flow cy-
tometry (A). The corresponding effect of stimulating cells with anti-CD54
is also shown (A, profile 4). In a separate experiment, cells were treated
with graded concentrations of ionomycin, and the peak Ca21 obtained at
each concentration was averaged over a 10-min period. The graph in B
depicts the mean (6SD) of four separate determinations. The line inter-
secting the graph indicates the mean Cai21 concentration obtained during
the EGTA-sensitive phase of anti-IgM-stimulated mobilization (A), where
the dashed lines above and below represent the SD from the mean (n 5 6).
C and D, Effects of indicated stimuli on cell surface densities of CD86 (C)
and CD80 (D). Cells, Unstimulated; aIg, anti-IgM; In, 0.5 mM ionomycin;
aCD, anti-CD54. Values presented are in terms of modal fluorescence in-
tensity (MFI) in B2201 gated cells for each group, and are the mean (6SD)
of four separate determinations.
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stimulation of B cells with anti-IgM had no significant effect on
cAMP concentrations (Fig. 4A). This was also true when ionomy-
cin was used instead (Fig. 4A). In contrast to this, addition of
anti-CD54 was found to produce a near 5-fold increase, implying
that CD54 stimulation also leads to accumulation of intracellular
cAMP in murine B cells (Fig. 4A). Interestingly, however, a com-
bination of anti-IgM and anti-CD54 as stimulants proved markedly
more effective, yielding a near 15-fold elevation in cAMP concen-
trations (Fig. 4A). In other words, although BCR triggering alone
was ineffective, it nevertheless appeared to synergize with CD54
stimulation to generate an amplified cAMP response. Equally sig-
nificant here was our finding that the synergistic effect of anti-IgM
on CD54-dependent cAMP accumulation could readily be dupli-
cated upon substituting it with 0.5 mM ionomycin (Fig. 4A). A
comparable extent of enhancement in intracellular cAMP concen-
trations was obtained regardless of whether anti-IgM or ionomycin
was used in conjunction with anti-CD54 (Fig. 4A). Based on these
latter results, we infer that anti-IgM-mobilized Cai21 constitutes at
least the principle mediator of the synergistic effects of anti-IgM
on CD54-dependent enhancement of intracellular cAMP. Consis-
tent with such an interpretation, the amplifying effects of both
anti-IgM and ionomycin on CD54-dependent cAMP accumulation
could be abolished by the simultaneous inclusion of EGTA in the
cultures. In both instances, the cAMP responses were similar to
that obtained upon stimulation with anti-CD54 alone (data not
shown).
To directly evaluate the consequences of enhanced cAMP con-
centrations on CD80 levels, we next used its analog db-cAMP.
However, to maintain equivalence with the native situation, we
sought to use db-cAMP at a concentration that would mimic the
effects of either anti-CD54 alone or that of anti-CD54 plus anti-
IgM. For this, titration experiments were first performed wherein
purified B cells were treated with varying concentrations of db-
cAMP, and the consequent intracellular levels then measured. The
results from such experiments are summarized in Fig. 4B. From
these results it was estimated that a 20 mM concentration of db-
cAMP would mimic the effects of anti-CD54 alone. In contrast, the
cAMP response upon dual stimulation with anti-CD54 and anti-
IgM (or ionomycin) could be duplicated by using db-cAMP at a
concentration of 100 mM (Fig. 4, compare A and B).
Our next objective was to assess the effect of the above titrated
doses of db-cAMP, either alone or in conjunction with other stim-
uli, on CD80 expression. The results from such experiments are
depicted in Fig. 4C, and several interesting aspects may be noted
here. Although the combined stimulation with anti-IgM and anti-
CD54 leads to amplified cAMP accumulation, this alone appeared
to be insufficient to explain the effect on CD80 levels. This became
evident from the fact that treatment of cells with 100 mM db-
cAMP alone had no significant effect on surface CD80 densities
(Fig. 4C). Interestingly, though, a combination of 100 mM db-
cAMP and anti-IgM proved extremely effective, producing an en-
hancement in CD80 levels that was comparable to that obtained
upon stimulation with anti-IgM plus anti-CD54 (Fig. 4C). In other
words, in addition to cAMP, up-regulation of CD80 also required
an added contribution from BCR-dependent pathways.
Another important finding in Fig. 4C was the fact that the stim-
ulus of anti-IgM could again be substituted with 0.5 mM ionomy-
cin, without any loss in potency. Thus the combination of 100 mM
db-cAMP and 0.5 mM ionomycin was as effective as the parent
stimulus of anti-CD54 plus anti-IgM at up-regulating CD80 on B
cells (Fig. 4C). Therefore, these data suggest that the BCR-mobi-
lized Cai21 by way of capacitative influx again constitutes the key
entity responsible for cooperating with cAMP-dependent path-
ways, to increase CD80 expression.
The cumulative results in Fig. 4 also reveal the existence of an
iterative interplay between BCR- and CD54-stimulated biochem-
ical pathways. In addition to implicating Cai21 and cAMP as the
two principal second messengers involved, these data also high-
light a sequential partitioning of function for the BCR-recruited
Cai21. At one level this Cai21 was found to synergize with CD54
stimulation to produce an amplified intracellular cAMP response
(Fig. 4A). However, subsequent to this, Cai21 again appeared to
integrate with pathways dependent upon cAMP, to yield an in-
crease in CD80 expression (Fig. 4C). That the synergistic cAMP
response was a necessary prerequisite to the latter effect is
supported by the data in Fig. 4C. As shown here, reducing the
db-cAMP concentration from 100 to 20 mM, a dose that mimics
the effects of anti-CD54 alone (Fig. 4B), during stimulation of
B cells with either db-cAMP and anti-IgM or with db-cAMP
and ionomycin, markedly reduced the efficiency of CD80 in-
duction (Fig. 4C).
BCR- and CD54-dependent pathways also converge to synergize
CREB phosphorylation at Ser133
The concerted action of Cai21 and cAMP signaling pathways on
CD80 expression was particularly intriguing, and deserved further
scrutiny. However, any information on the transcription factors
that directly regulate activation of the CD80 gene is currently lack-
ing. Furthermore, considering the delayed kinetics of induction of
CD80 as shown in Fig. 1Ac, it is entirely possible that these two
pathways act on early transcriptional events, which then regulate
CD80 concentrations either at the level of transcript stabilization
or de novo synthesis. Therefore, as an alternative, we explored the
effects on phosphorylation of CREB. Activation of CREB has been
shown to minimally require its phosphorylation on a Ser residue at
position 133 (38–40).
Although it is not known whether CREB in fact influences
CD80 expression, several reasons prompted us to choose this par-
ticular protein. We have recently identified an octamer sequence
(sequence: TGATGTCA) located 713 bp upstream of the tran-
scription start site in the murine CD80 gene, that is capable of
binding to CREB in gel-shift assays (K. Natarajan, and K.V.S.
Rao, unpublished results). Importantly we found that the induction
of CD80 by the combination of anti-IgM plus anti-CD54 could be
completely inhibited by the addition of H89, an inhibitor of the
cAMP-dependent kinase, protein kinase A (PKA) (41, 42). As
shown in Fig. 5, the inhibition was specific for CD80, and was
exercised at the level of both cell surface protein and the corre-
sponding mRNA. Because CREB is known to represent the prin-
cipal substrate for PKA activity (39–41), these findings may im-
plicate, albeit indirectly, a possible role for this transcription factor
during CD80 regulation. Finally, it has been shown that Ser133 of
CREB serves as a target for both BCR- and cAMP-dependent
pathways in B cells (38, 43). As a result it was anticipated that, at
the minimum, CREB could serve as a useful substrate to demon-
strate the existence of cooperativity between BCR- and CD54-
stimulated pathways.
It has previously been demonstrated that stimulation of murine
B lymphoma cells with anti-IgM results in phosphorylation of
CREB at Ser133 (38). The predominant kinase implicated in this
appeared to be protein kinase C (PKC) rather than PKA, as iden-
tified by the effects of specific inhibitors (38). Consistent with
these findings, we observed that stimulation of splenic B cells with
anti-IgM also induced Ser133 phosphorylation of CREB, although
the magnitude of this response was significantly lower (;3-fold)
(Fig. 6A). Furthermore, this phosphorylation was inhibited to ap-
proximately equal extents (between 30 and 40%) by the addition of
either the calmodulin-dependent kinase II/IV inhibitor KN-62 (44,
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45) or the PKC inhibitor calphostin C (46) (Fig. 6A). No significant
effect of the PKA inhibitor, H89, could be detected (Fig. 6A).
Thus, anti-IgM-stimulated phosphorylation of CREB on Ser133 in
B cells appears to be mediated, at least largely, by the combined
activities of calmodulin-dependent kinase II/IV and PKC. Consis-
tent with this, addition of a mixture of KN-62 and calphostin C
completely abrogated anti-IgM-dependent CREB phosphorylation
(Fig. 6A).
In similarity to anti-IgM, stimulation with anti-CD54 also led to
a near 5-fold enhancement in Ser133-phosphorylated CREB levels
(Fig. 6B). However, in this case the effect appeared to be princi-
pally mediated by PKA because addition of H89 yielded near com-
plete inhibition, whereas neither KN-62 nor calphostin C had any
detectable effect (Fig. 6B)). In other words, although both anti-IgM
and anti-CD54 individually drive CREB phosphorylation at
Ser133, they apparently recruit distinct protein kinases to
achieve this.
In comparison with the relatively weak individual potencies of
anti-IgM and anti-CD54, simultaneous activation with both of
these stimuli produced a markedly pronounced effect, yielding a
near 20-fold enhancement in levels of the Ser133-phosphorylated
form of CREB (Fig. 7A). Interestingly, partial inhibition of this
effect was obtained with KN-62 (25%), calphostin C (20%), or
H89, although the effects of H89 were the most pronounced, where
inhibition was .75% (Fig. 7A). Simultaneous addition of all three
of these inhibitors resulted in a complete inhibition of phosphor-
ylation (Fig. 7A). Thus, the synergistic effects of anti-IgM and
anti-CD54 on the phosphorylation status of CREB appear to reflect
the cumulative effects of the protein kinases individually recruited
by these stimuli. However, it was notable that a substantial pro-
portion of the enhanced phosphorylation of CREB at Ser133 was
dependent upon PKA activity (Fig. 7A).
The synergistic influence of anti-IgM and anti-CD54 seen in
Fig. 7A could also be duplicated by substituting these stimuli with
0.5 mM ionomycin and 100 mM db-cAMP, respectively (Fig. 7B).
Notably, the effects of the various inhibitors tested also yielded
results comparable with that obtained for anti-IgM plus anti-CD54
stimulation (Fig. 7, compare A and B). Thus, although KN-62 and
calphostin C inhibited CREB phosphorylation at Ser133 by 25 and
20%, respectively, inhibition by H89 was by as much as 80%. At
one level, these data confirm that, in similarity with CD80 induc-
tion, Cai21 and cAMP again constitute the principal intracellular
mediators that direct the downstream effects of BCR and CD54
ligation on CREB phosphorylation. This is particularly highlighted
by the fact that the kinase intermediates recruited by ionomycin
plus db-cAMP in this process are the same as those mobilized by
anti-IgM plus anti-CD54. In either case a biased requirement for
PKA activity could also be noted. Therefore, the results in Fig. 7
clearly identify the existence of a productive cross-talk between
BCR-stimulated Cai21 and intracellular cAMP signaling path-
ways. This synergy, in turn, is capable of potentiating biochemical
responses, at least in terms of CREB phosphorylation.
Cross-talk between second messengers overcomes individual
concentration threshold barriers
Although our present data demonstrate the requirement for syner-
gistic interactions between Cai21 and cAMP to facilitate CD80
up-regulation we took note of the fact that these second messen-
gers have also been shown to be capable of independently inducing
FIGURE 5. The PKA inhibitor, H89, inhibits CD80 but not CD86 up-
regulation. A, Effects of H89 addition on anti-IgM-mediated induction of
CD86 (a) and anti-IgM plus anti-CD54-dependent up-regulation of CD80
(b), respectively. In both cases the thin line represents unstimulated cells,
whereas the thick line represents either CD86 (a) or CD80 (b) in appro-
priately stimulated cells. In both cases, the dashed line depicts the corre-
sponding levels when the cells were stimulated in the presence of H89 (100
nM, 23 IC50). B, Northern blot analyses for either CD86 (a) or CD80 (b)
mRNAs obtained in the individual groups. Parallel analysis for the b-actin
message confirmed comparable loading in all cases, although these results
are not shown here. Data presented are from one of three separate
experiments.
FIGURE 6. Effects of anti-IgM and anti-CD54 on CREB phosphoryla-
tion in B cells. Purified B cells were stimulated with anti-IgM (A) or with
anti-CD54 (B) either in the presence or absence of the indicated protein
kinase inhibitors as described in Materials and Methods. Subsequently
prepared nuclear extracts were then resolved by gel electrophoresis, and the
extent of CREB phosphorylation was determined by Western blot analysis
using Abs specific for Ser133-phosphorylated CREB (Materials and Meth-
ods). Following this, bound Ab was eluted, and the blots were reprobed
with Abs against the CREB protein. The extent of enhancement in Ser133-
phosphorylation was determined by densitometric scanning of the resulting
autoradiograms, and is presented as fold induction over that in unstimu-
lated cells after normalizing for CREB protein levels in each lane. Values
are the mean (6SD) of three independent determinations. Cal-C, Calphos-
tin C.
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CD80 expression. For example, stimulation of B lymphoma cells
with db-cAMP alone has been reported to induce surface CD80
expression (36). In a similar vein, stimulation of chronic myelog-
enous leukemia myeloid progenitor cells with a calcium ionophore
has also been found to result in CD80 up-regulation (47). How-
ever, in both cases the concentrations of stimulators used were
significantly higher than those used in this study (36, 47). There-
fore, it occurred to us that the cross-talk between Cai21 and cAMP
may well serve to minimize individual concentrations required for
the induction of CD80 expression.
To examine for such a possibility, purified B cells were inde-
pendently stimulated with varying concentrations of either iono-
mycin or db-cAMP. In addition, for comparative purposes, a par-
allel set of cells was also stimulated with the combination of 0.5
mM ionomycin and 100 mM db-cAMP. The extent of surface
CD80 induction in each of these cases was then assessed, and the
cumulative results are presented in Fig. 8. However, although both
db-cAMP and ionomycin were independently capable of produc-
ing enhanced CD80 expression, their efficiency was poor (Fig. 8).
Relatively higher concentrations of either of these two agents were
required to produce a significant effect (Fig. 8). In contrast to this,
the combination of ionomycin and db-cAMP proved extremely
effective, yielding optimal CD80 enhancement with only subopti-
mal concentrations of the individual stimuli (Fig. 8). Therefore,
these results reveal that the concerted action of second messenger-
dependent signaling modules can subvert concentration thresholds
required for independent action, at least in the context of CD80
regulation.
Discussion
Although studies continue to detail the early biochemical events
initiated upon BCR cross-linking, the importance of modulation of
these pathways by accessory signals is also being increasingly re-
alized. One way of viewing the signaling cascades, initiated upon
stimulation of a given cell surface molecule, can be as analogous
to the wave fronts generated upon perturbation at a single source.
In such a case, the interference between ‘wave-fronts’ of indepen-
dent origin may then be expected to lead to either a ‘constructive’
or “destructive” outcome. A good example of the former is the
coligation of BCR with the CR2/CD19/TAP-1 complex, where
B cell responsiveness is heightened (15, 16). In contrast, the cross-
linking of BCR with the FcgRIIb coreceptor, where B cell respon-
siveness is attenuated (17–20), may be considered as a case
resulting from destructive interference.
Although the existence of signal interference is now well estab-
lished, our understanding of the various modes by which they can
occur is sparse. It was with the intent of gaining additional insights
into this aspect within B lymphocytes that this study was under-
taken. It was anticipated that our present experimental system, us-
ing anti-IgM and anti-CD54 as the stimuli, would shed light on
how BCR-dependent pathways service CD86 expression on the
one hand, and concomitantly integrate with CD54-dependent path-
ways to modulate CD80 levels on the other.
The identification of Cai21 as an obligatory mediator for the
induction of both CD80 and CD86 provided us with a reference
point for further study. This was particularly true given that this
intermediate was solely a product of BCR-triggering, where the
second phase of recruitment—by capacitative influx—proved to
be at least sufficient to account for the effects of anti-IgM. It was
at this stage of our investigations that at least two distinct effector
modes for BCR-mobilized Cai21 had become apparent. On the one
hand, this second messenger was independently capable of driving
CD86 up-regulation. Direct evidence in support of such a conclu-
sion could be afforded by experiments wherein stimulation of B
cells with a pretitrated dose of ionomycin proved to be as potent as
anti-IgM in this effect. However, in addition to this, BCR-depen-
dent Cai21 was also shown to act in concert with CD54-driven
pathways to provide for an amplified cAMP response. It was this
increased accumulation of intracellular cAMP that then set the
stage for a second round of cooperativity between Cai21 and
cAMP, resulting in enhanced surface expression of CD80. The
direct involvement of both Cai21 and cAMP in the latter process
could be substantiated by the fact that a combination of ionomycin
and db-cAMP at their predefined concentrations was as effective as
FIGURE 7. Phosphorylation of CREB on Ser133 in stimulated B cells. A, Results of a Western blot analysis for CREB in either unstimulated cells (lane
1) or cells that were stimulated with anti-IgM (lane 2), anti-CD54 (lane 3), or with a combination of anti-IgM plus anti-CD54 (lane 4). Additional sets also
include cells stimulated with anti-IgM plus anti-CD54 in the presence of the inhibitors KN-62 (lane 5), Calphostin C (lane 6), H89 (lane 7), or a combination
of all three inhibitors (lane 8) (Materials and Methods). Top, Results obtained using Abs specific for the Ser133-phosphorylated form of CREB (P-CREB).
Subsequent to this, bound Abs were eluted, and the blots were probed once again with Abs against the CREB protein (bottom, CREB). B, Results of a similar
experiment except that cells were stimulated with 0.5 mM ionomycin (lane 2), 100 mM db-cAMP (lane 3), or a combination of both (lane 4). Results for
parallel sets of cells stimulated with 0.5 mM ionomycin plus 100 mM db-cAMP in the presence of KN-62 (lane 5), Calphostin C (lane 6), H89 (lane 7),
or a combination of all three inhibitors (lane 8). Unstimulated cells are represented in lane 1. Data are a representative of five separate experiments.
FIGURE 8. Thresholds for Cai21 and cAMP for induction of CD80.
Purified B cells were stimulated with indicated concentrations of either
ionomycin (Iono, E) or db-cAMP (F). Following this, the subsequent ex-
pression of surface CD80 was monitored by flow cytometry. In addition, a
parallel set of cells was also treated with a combination of 0.5 mM iono-
mycin and 100 mM db-cAMP for comparative purposes. The resultant
enhancement in surface CD80 expression is shown by the open column.
Values are the mean (6SD) of five separate experiments.
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the parent stimulus of anti-IgM plus anti-CD54 at up-regulating
CD80 levels.
The interactions between BCR-mobilized Cai21- and CD54-de-
pendent signaling pathways could also be evidenced at the level of
phosphorylation of CREB on Ser133. Although a role for CREB in
CD80 regulation is yet to be demonstrated, these results at the very
least provide biochemical confirmation for the productive nature of
this interaction. Although the increase in Ser133 phosphorylation of
CREB, due to activation of cells with anti-IgM plus anti-CD54,
was found to involve kinase intermediates independently recruited
by the individual stimuli, the observed predominant involvement
of PKA activity is intriguing. It would be interesting to see whether
the potentiatory effects of anti-IgM plus anti-CD54 stimulation are
also exercised at the level of PKA activation. Importantly though,
this synergistic effect could be demonstrated to be again mediated
by the two second messengers, Cai21 and cAMP, providing addi-
tional evidence for a constructive interference between these two
signaling modules.
It has been previously reported in murine B cells that enhance-
ment of intracellular cAMP levels before BCR ligation has inhib-
itory effects on both 1,4,5-inositol triphosphate generation and
Cai21 mobilization (48). From this the existence of a cross-talk
between cAMP- and BCR-dependent phosphoinositol signaling
pathways was inferred (48). Although present data confirm the
existence of such a cross-talk, they also suggest that the outcome
of this process is strictly dependent upon the timing at which these
two pathways are initiated. Thus, in contrast to the attenuating
effects of sequential triggering, simultaneous initiation leads to po-
tentiation of at least some of the subsequent responses. However,
the biochemical interactions mediating this cross-talk remain un-
known, and would clearly be of interest to delineate.
In addition to the above, our present characterization of the in-
teractions between BCR- and CD54-dependent pathways also pro-
vides a novel insight into the networking of independently gener-
ated signaling modules. As the data suggests, this constitutes a
sequential process that is initiated by a cross-talk between the two
pathways. The consequence of this interaction then, is to directly
promote a second round of synergy and thereby facilitate CD80
up-regulation. In other words, these findings reveal the existence
of “dialectical” modes of signal interference, which can contribute
toward gain of function for the target cell.
Finally, our delineation of differences in both the concentration
and spectrum of the regulatory intermediates involved during ex-
pression of CD80 and CD86 provides an empirical explanation for
their distinct induction thresholds. Although CD86 expression
could be achieved through a relatively moderate augmentation in
Cai21, concomitant induction of CD80 required the added support
from cAMP recruitment. Our observation that cross-talk between
Ca- and cAMP-signaling pathways modulates individual concen-
trations required for CD80 up-regulation is also particularly rele-
vant. Thus, in principle, either independent mobilization of any of
these mediators at optimal concentrations, or simultaneous recruit-
ment of both at suboptimal concentrations, should render CD80
expression permissive at least in B cells. It is likely, then, that the
versatility offered by such multiple options may well constitute the
wherewithal for “intelligent decision-making” when responding to
external stimuli.
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